|Bid||67.55 x 1000|
|Ask||67.64 x 1400|
|Day's range||67.61 - 68.60|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||16.56|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.84 (4.17%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||76.03|
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.
FOSTER CITY, Calif., October 15, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease. The final European Commission decision on
FOSTER CITY, Calif., October 14, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2021 financial results will be released on Thursday, October 28, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2021 financial results and will provide a business update.